Granules India Limited (GRANULES.BO)
INR 475.8
(-0.77%)
INR 475.8
(-0.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.18 Billion INR | -25.01% |
| 2022 | 13.75 Billion INR | 15.24% |
| 2021 | 11.93 Billion INR | 16.37% |
| 2020 | 10.25 Billion INR | 27.38% |
| 2019 | 8.05 Billion INR | 20.14% |
| 2018 | 6.7 Billion INR | 32.42% |
| 2017 | 5.06 Billion INR | 6.71% |
| 2016 | 4.74 Billion INR | 22.23% |
| 2015 | 3.87 Billion INR | 29.34% |
| 2014 | 2.99 Billion INR | 18.42% |
| 2013 | 2.53 Billion INR | 43.57% |
| 2012 | 1.76 Billion INR | 1.49% |
| 2011 | 1.73 Billion INR | 270.37% |
| 2010 | 469.37 Million INR | 2.6% |
| 2009 | 457.47 Million INR | 0.0% |
| 2008 | - INR | -100.0% |
| 2007 | 263.82 Million INR | 55.88% |
| 2006 | 169.24 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.72 Billion INR | -8.78% |
| 2023 Q4 | 2.98 Billion INR | -35.07% |
| 2023 Q3 | 4.6 Billion INR | 1.38% |
| 2023 FY | 10.31 Billion INR | -25.01% |
| 2023 Q1 | 4.18 Billion INR | 43.12% |
| 2023 Q2 | 4.53 Billion INR | 8.4% |
| 2022 Q4 | 2.92 Billion INR | -21.23% |
| 2022 Q3 | 3.71 Billion INR | -0.52% |
| 2022 FY | 13.75 Billion INR | 15.24% |
| 2022 Q1 | 3.37 Billion INR | 48.78% |
| 2022 Q2 | 3.73 Billion INR | 10.51% |
| 2021 Q4 | 2.27 Billion INR | -31.25% |
| 2021 Q1 | 2.98 Billion INR | 63.06% |
| 2021 FY | 11.93 Billion INR | 16.37% |
| 2021 Q3 | 3.3 Billion INR | -2.96% |
| 2021 Q2 | 3.4 Billion INR | 13.95% |
| 2020 Q1 | 2.88 Billion INR | 112.81% |
| 2020 Q2 | 2.76 Billion INR | -4.1% |
| 2020 Q4 | 1.83 Billion INR | -34.29% |
| 2020 FY | 10.25 Billion INR | 27.38% |
| 2020 Q3 | 2.78 Billion INR | 0.77% |
| 2019 Q4 | 1.35 Billion INR | -41.75% |
| 2019 Q1 | 2.09 Billion INR | 53.68% |
| 2019 Q3 | 2.32 Billion INR | 2.6% |
| 2019 Q2 | 2.26 Billion INR | 8.09% |
| 2019 FY | 8.05 Billion INR | 20.14% |
| 2018 Q3 | 1.86 Billion INR | -1.49% |
| 2018 FY | 6.7 Billion INR | 32.42% |
| 2018 Q1 | 1.58 Billion INR | -7.51% |
| 2018 Q2 | 1.89 Billion INR | 19.69% |
| 2018 Q4 | 1.36 Billion INR | -26.71% |
| 2017 Q1 | 1.39 Billion INR | -0.41% |
| 2017 FY | 5.06 Billion INR | 6.71% |
| 2017 Q4 | 1.7 Billion INR | 15.94% |
| 2017 Q3 | 1.47 Billion INR | 7.93% |
| 2017 Q2 | 1.36 Billion INR | -1.87% |
| 2016 FY | 4.74 Billion INR | 22.23% |
| 2016 Q4 | 1.39 Billion INR | 8.54% |
| 2016 Q3 | 1.28 Billion INR | 6.69% |
| 2016 Q2 | 1.2 Billion INR | 3.16% |
| 2016 Q1 | 1.16 Billion INR | 2.32% |
| 2015 FY | 3.87 Billion INR | 29.34% |
| 2015 Q4 | 1.14 Billion INR | 37.98% |
| 2015 Q2 | 795.69 Million INR | 0.85% |
| 2015 Q1 | 788.96 Million INR | 5.06% |
| 2015 Q3 | 828.4 Million INR | 4.11% |
| 2014 Q4 | 750.96 Million INR | -3.66% |
| 2014 Q3 | 779.47 Million INR | 2.89% |
| 2014 Q2 | 757.61 Million INR | 9.13% |
| 2014 FY | 2.99 Billion INR | 18.42% |
| 2014 Q1 | 694.2 Million INR | 4.64% |
| 2013 Q3 | 673.37 Million INR | 0.52% |
| 2013 Q4 | 663.44 Million INR | -1.47% |
| 2013 Q2 | 669.86 Million INR | 27.26% |
| 2013 Q1 | 526.39 Million INR | -59.56% |
| 2013 FY | 2.53 Billion INR | 43.57% |
| 2012 Q3 | 432.85 Million INR | 1.66% |
| 2012 Q4 | 1.3 Billion INR | 200.72% |
| 2012 FY | 1.76 Billion INR | 1.49% |
| 2012 Q1 | 409.88 Million INR | 0.0% |
| 2012 Q2 | 425.78 Million INR | 3.88% |
| 2011 FY | 1.73 Billion INR | 270.37% |
| 2010 FY | 469.37 Million INR | 2.6% |
| 2009 FY | 457.47 Million INR | 0.0% |
| 2008 FY | - INR | -100.0% |
| 2007 FY | 263.82 Million INR | 55.88% |
| 2006 FY | 169.24 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bal Pharma Limited | 389.89 Million INR | -1742.153% |
| Achyut Healthcare Limited | 1.6 Million INR | -446287.197% |
| Alkem Laboratories Limited | 32.83 Billion INR | 78.126% |
| Divi's Laboratories Limited | 14.17 Billion INR | 49.313% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 89.37% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 38.299% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -15461.075% |
| Mankind Pharma Limited | 23.15 Billion INR | 68.978% |
| Medicamen Biotech Limited | 335.16 Million INR | -2042.923% |
| Medico Remedies Limited | 161.84 Million INR | -4337.835% |
| Megasoft Limited | 49.52 Million INR | -14401.636% |
| Procter & Gamble Health Limited | 2.99 Billion INR | -139.78% |
| Piramal Pharma Limited | 19.91 Billion INR | 63.933% |
| Sequent Scientific Limited | 2.9 Billion INR | -147.513% |
| Sigachi Industries Limited | 579.88 Million INR | -1138.581% |
| Ajanta Pharma Limited | 30.46 Billion INR | 76.422% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 95.342% |
| Brooks Laboratories Limited | 51.18 Million INR | -13933.548% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | -133.619% |
| Themis Medicare Limited | 782.85 Million INR | -817.459% |
| Unichem Laboratories Limited | 6.72 Billion INR | -6.787% |
| Hester Biosciences Limited | 908.84 Million INR | -690.279% |
| Venus Remedies Limited | 1.91 Billion INR | -274.807% |
| Indoco Remedies Limited | 4.74 Billion INR | -51.247% |
| Ind-Swift Limited | 946.56 Million INR | -658.781% |
| Aarti Drugs Limited | 1.16 Billion INR | -515.203% |
| Alpa Laboratories Limited | 156.14 Million INR | -4499.749% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | -176.203% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 92.509% |
| Gufic Biosciences Limited | 1.07 Billion INR | -566.447% |
| Hikal Limited | 2.48 Billion INR | -188.873% |
| RPG Life Sciences Limited | 1.63 Billion INR | -339.154% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -412.006% |
| Windlas Biotech Limited | 1 Billion INR | -613.592% |
| ZIM Laboratories Limited | 1.01 Billion INR | -608.979% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -238.124% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -553.656% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 50.309% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 81.694% |
| Bajaj HealthCare Limited | 985.34 Million INR | -628.919% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -44209.089% |
| Ipca Laboratories Limited | 13.91 Billion INR | 48.384% |
| Lasa Supergenerics Limited | 291.17 Million INR | -2366.693% |
| Laurus Labs Limited | 3.01 Billion INR | -138.554% |
| NATCO Pharma Limited | 10.05 Billion INR | 28.59% |
| Nectar Lifesciences Limited | 625.55 Million INR | -1048.169% |
| Shilpa Medicare Limited | 2.18 Billion INR | -229.378% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | -56.831% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 66.472% |
| Wanbury Limited | 1.16 Billion INR | -518.675% |
| Wockhardt Limited | 6.4 Billion INR | -12.225% |
| Strides Pharma Science Limited | 9.16 Billion INR | 21.61% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -406.078% |
| Suven Life Sciences Limited | 109.75 Million INR | -6444.301% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -553.544% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 54.742% |
| Eris Lifesciences Limited | 4.94 Billion INR | -45.306% |
| Lupin Limited | 95.67 Billion INR | 92.493% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | -133.436% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -662.137% |
| Valiant Laboratories Limited | 36.28 Million INR | -19692.141% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 83.364% |
| FDC Limited | 5.34 Billion INR | -34.287% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 14.669% |
| Novartis India Limited | 470.1 Million INR | -1427.839% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -828.663% |
| Neuland Laboratories Limited | 2.92 Billion INR | -145.153% |
| Morepen Laboratories Limited | 1.98 Billion INR | -261.386% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -1641.489% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -962.25% |